PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.
Phase: PHASE3
Conditions: High Blood Pressure (& [Essential Hypertension])
Sponsor: Laboratorios Richmond S.A.C.I.F.

Official Study Title: PHASE III, RANDOMIZED, ACTIVE-COMPARATOR 
CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY 
OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS 
DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.
Protocol Number: NIF30-0120
Protocol Version: Version 3
Document Date: 23-Aug-2023
NCT Number: To be confirmed
Date: 26th february 2026
Dear ClinicalTrials.gov Registration Team,
Please find att
-
COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE 
EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN 
ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION 
l NIF30-0120, Version 3, dated 23-Aug-2023, submitted 
for registration purposes.
The NCT number is currently pending confirmation and will be provided once 
available.
Should you require any additional information or documentation, please do not 
hesitate to contact me.
Sincerely,
Trinidad Plata B.
MSL Laboratorios Richmond Colombia 
tplata@richmondlab.com